Molecular Epidemiology of Group A Streptococcus Infections in The Gambia
Open Access
- 4 February 2021
- Vol. 9 (2), 124
- https://doi.org/10.3390/vaccines9020124
Abstract
Molecular epidemiological data on Group A Streptococcus (GAS) infection in Africa is scarce. We characterized the emm-types and emm-clusters of 433 stored clinical GAS isolates from The Gambia collected between 2004 and 2018. To reduce the potential for strain mistyping, we used a newly published primer for emm-typing. There was considerable strain diversity, highlighting the need for vaccine development offering broad strain protection.Funding Information
- Wellcome Trust (206061/Z17Z)
This publication has 11 references indexed in Scilit:
- Systematic Review and Meta-analysis of the Prevalence of Group A Streptococcal emm Clusters in Africa To Inform Vaccine DevelopmentmSphere, 2020
- Updated emm-typing protocol for Streptococcus pyogenesClinical Microbiology & Infection, 2020
- Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomicsNature Genetics, 2019
- Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection studyVaccine, 2019
- The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product CharacteristicsClinical Infectious Diseases, 2019
- Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015The New England Journal of Medicine, 2017
- A Systematic and Functional Classification of Streptococcus pyogenes That Serves as a New Tool for Molecular Typing and Vaccine DevelopmentThe Journal of Infectious Diseases, 2014
- Group A streptococcal vaccines: Paving a path for accelerated developmentVaccine, 2013
- Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?Expert Review of Vaccines, 2009
- Global emm type distribution of group A streptococci: systematic review and implications for vaccine developmentThe Lancet Infectious Diseases, 2009